

GSK Pharmaceutical Industry  
**Fellowship Program**

2020

## Cover image

---

We aim to achieve industry-leading growth by investing effectively in our business, developing our people, and striving for innovation.

We commit to scientific and technical excellence by developing new products that meet the needs of patients, payers, and consumers.

## Table of contents

<b>Introduction</b>	<b>2</b>
<b>GSK</b>	<b>3</b>
<b>UNC Eshelman School of Pharmacy</b>	<b>6</b>
<b>Fellowships</b>	<b>8-13</b>
▪ US Medical Affairs	<b>8</b>
▪ Global Regulatory Affairs	<b>10</b>
▪ Pharmacokinetics/Pharmacodynamics	<b>12</b>
<b>UNC GSK Fellowship Alumni</b>	<b>14-15</b>
<b>Application and Eligibility</b>	<b>16</b>

## Introduction

**The fellowship programs, in partnership with UNC Eshelman School of Pharmacy and GSK, aim to develop pharmaceutical industry professionals to become successful leaders and innovators**

The fellowship programs are two years in length, thus enabling fellows to develop a strong scientific foundation in areas of interest and apply practical knowledge in the setting of pharmaceutical drug development. There is an emphasis on ensuring direct contribution to the advancement of the pharmaceutical sciences as related to the field of study.

GSK has a rich history of collaborations with a variety of leading academic institutions through sponsorship of joint fellowship programs.



**Fellowships offered by GSK in partnership with UNC Eshelman School of Pharmacy include:**

**US Medical Affairs**  
(PharmD or PhD)

**Global Regulatory Affairs**  
(PharmD, PhD, or MD)

**Pharmacokinetics/  
Pharmacodynamic**  
(PharmD, PhD, or MD)




**We are one of the largest global pharmaceutical companies**

Today there are millions of people without access to basic healthcare, thousands of diseases without adequate treatments and millions of people who suffer from everyday ailments. We want to change this. That's why we are harnessing our scientific and technical know-how, our talented people, our partnerships, and our global reach to develop and manufacture healthcare products for people who need them.

**Our mission is to improve the quality of human life by enabling people to do more, feel better, and live longer.**

## Our DNA



### Our strategy

Bring quality, needed healthcare products to as many people as possible, with our scientific and technical know-how and talented people.

# GSK at a glance



## Who we are

A science-led global healthcare company with a special purpose to help people do more, feel better, live longer.

We have three global businesses that discover, develop and manufacture innovative pharmaceutical medicines, vaccines and consumer healthcare products.

Our goal is to become one of the world's most innovative, best performing and trusted healthcare companies.



Snider-Desir  
Scientific Investigator

## What we do

We aim to bring differentiated, high-quality and needed healthcare products to as many people as possible, with our three global businesses, scientific and technical know-how and talented people.

In 2019

£33.8bn

total sales

£4.6bn

R&D investment

£3.8bn


Innovation sales from pharmaceutical and vaccine products launched in the last five years

50

medicines(35) and vaccines(15) in the pipeline, including treatments for HIV, respiratory disease and oncology (as of July 2020)

### Pharmaceuticals


Our Pharmaceuticals business has a broad portfolio of innovative and established medicines in respiratory, HIV, immunoinflammation and oncology. We are strengthening our R&D pipeline through a focus on immunology, human genetics and advanced technologies to help us deliver transformational new medicines for patients.



Antibody with cytotoxic drug attached

### Vaccines


We are the world's largest vaccines company\*, delivering vaccines that help protect people at all stages of life. Our R&D focuses on developing vaccines against infectious diseases that combine high medical need and strong market potential.



Herpes zoster virus of shingles

### Consumer Healthcare

Our world-leading Consumer Healthcare business combines science and consumer insights to create innovative everyday healthcare brands that consumers trust and experts recommend for oral health, pain relief, cold, flu and allergy, digestive health and vitamins, minerals and supplements.



Nociceptors, the sensors of the pain pathway

# How we do it

Everyone at GSK is focused on our three long-term priorities.

## Innovation

We invest in scientific and technical excellence to develop and launch a pipeline of new products that meet the needs of patients, payers and consumers.

## Performance

We deliver growth by investing effectively in our business, developing our people and executing competitively.

## Trust

We are a responsible company – using our science and technology to address health needs, we are focused on making our products affordable and available, and being a modern employer.

### Our global response in the fight against COVID-19



We are using our science, technology, portfolio and resources to support development of products for prevention and treatment of COVID-19.

Our primary aim is to support the development of multiple adjuvanted COVID-19 vaccines, and we plan to produce 1 billion vaccine adjuvant doses in 2021. We are combining our expertise and scale with scientific partners from around the world including North America, China and Europe. Our adjuvant technology can boost the body's immune response, so less vaccine is needed for the same result and more people can be protected.

### Shingles



Our shingles vaccine, which reached sales of £1.8bn in 2019, is now the most successful biopharma launch of the last 10 years.

### HIV



1.7 million children living with HIV have limited treatment options. In 2019 we filed for approval of a new formulation of our innovative dolutegravir medicine to simplify, optimise and extend its use in babies and children living with HIV.

## Our Culture

Our values and expectations are at the heart of everything we do – so that together we can deliver extraordinary impact for patients and consumers and make GSK a brilliant place to work.

### Our values

- Patient focus
- Transparency
- Respect
- Integrity

### Our expectations

- Courage
- Accountability
- Development
- Teamwork

# Why we do it

To help millions of people around the world to do more, feel better, live longer.



Kimberley  
Ovarian cancer patient



# UNC PARTNERSHIP

The UNC Eshelman School of Pharmacy, ranked as the #1 pharmacy school in the nation by the US News and World Report 2020, is a nationally recognized leader in progressive pharmaceutical care practice, education, and research. We are committed to building a diverse talent pipeline. Our global inclusion and diversity councils are driving our agenda.



## CHAPEL HILL, NC

The Eshelman School of Pharmacy is part of the University of North Carolina at Chapel Hill, a major research university with a large academic medical center. The School of Pharmacy has specialized research centers pursuing advancements in drug delivery, nanotechnology cancer treatment, pharmacogenomics, and medication optimization.

The Chapel Hill campus is close to the RTP business region, and several large health systems. It offers a rich blend of culture, entertainment, recreation, fine dining, and some of the best college basketball action in the country.



## RESEARCH TRIANGLE PARK (RTP), NC

UNC anchors one corner of North Carolina's famed RTP which hosts an abundance of pharmaceutical, biotechnology, and healthcare companies. This environment offers opportunities for collaboration in research, education, and patient care with partners in academia, industry, and healthcare.

RTP is the largest GSK commercial site that operates in the US and houses critical roles in pharmaceuticals, corporate, and manufacturing functions, as well as Research and Development (R&D) and ViiV Healthcare.

US Medical Affairs fellows gain pharmaceutical industry experience during the second year of the fellowship program at RTP. Global Regulatory Affairs fellows spend 2 years with their sponsor company.



"Year after year, I am in awe of our fellows' initiative and innovation and the unique hands-on learning opportunities afforded to them by the University and GSK."

Jo Ellen Rodgers, PharmD, BCPS, FCCP

**Global Regulatory Affairs (GRA) fellows may be based out of UP or Waltham, based on business need, throughout the 2-year duration of the fellowship program.**



## **UPPER PROVIDENCE (UP) / COLLEGEVILLE, PA**

The Upper Providence GSK site, which is the US R&D Hub, is named for its location in Upper Providence Township, Montgomery County, Pennsylvania. It is approximately 30 miles northwest of Center City Philadelphia and approximately 35 miles from Philadelphia International Airport.

Pharmacokinetics/ Pharmacodynamics (PK/PD) fellows relocate to UP after their first year at UNC. At UP, GRA and PK/PD fellows gain hands-on pharmaceutical industry experience in a highly dynamic work environment.



## **WALTHAM, MA**

The Waltham location, previously known as Tesaro, was acquired by GSK in 2019 to strengthen the oncology pipeline and has become a pivotal R&D location. It is located approximately 15 miles northwest of downtown Boston.

"Each year, for more than three decades, we have an incredible group of fellows, who make a significant contribution to the legacy of our program. These fellows are a reflection of UNC and GSK's strong long-standing commitment to train and develop the newest generation of pharmaceutical industry professionals."

Robert Dupuis, PharmD, FCCP





## US Medical Affairs fellowship

**The US Medical Affairs fellowship at GSK provides the practical training and experience needed to successfully obtain a position in the pharmaceutical industry, academia, clinical practice, or Contract Research Organizations**

Fellows will work in a cross-functional matrix team which consists of the US Medical Affairs Lead, therapy area scientific/medical directors, global medical affairs, global clinical safety and pharmacovigilance, regulatory affairs, legal, health outcomes, research and development, and commercial.



### Fellowship objectives

- Work closely with US Medical Affairs Leads and Accountable Medical Leads to execute tactics that support the overall medical strategy
- Understand principles of clinical research, apply clinical trial design strategies, and collect and analyze data
- Conduct strategic reviews of the medical literature and the competitive environment to identify data and educational gaps to enhance patient care
- Contribute to US scientific engagement between GSK and external communities to advance the understanding of disease treatment and management
- Participate in the medical review of promotional materials and communicate scientific information to internal and field based colleagues
- Support launch preparations for new medicines and/or new indications or label extensions

## Program structure

### Year one

At UNC Eshelman School of Pharmacy, fellows will have the opportunity to

- Review the principles of clinical research, such as Good Clinical Practice (GCP) and gain an understanding of the wellbeing of study subjects, data collection, analysis, and safety reporting
- Apply clinical design strategies, evaluate research designs and study reports, and utilize biostatistical tests
- Develop protocols, recruit and monitor subjects, collect and analyze data, and prepare an academic manuscript

### Year two

At GSK within US Medical Affairs, fellows will have the opportunity to

- Understand the decision-making process that healthcare providers and payers follow for drug utilization
- Contribute to the development and execution of US Medical Affairs plans and integrate the voice of the customer including, providers, payers, patients, into a medical affairs strategy
- Gain clinical knowledge and product expertise in a therapeutic area

### Program Director



**Antoinette Burgess, PharmD**  
Head of Medical Stakeholder  
Engagement and Communication,  
US Medical Affairs, GSK




"The partnership between UNC and GSK provides a unique development opportunity. Fellows gain practical experience with the drug development and clinical trial process in an academic university setting and then apply those learnings within a pharmaceutical industry setting in US Medical Affairs. Our Fellows make a significant contribution as they develop on their journey with us and it helps to shape their overall professional careers."

**Antoinette Burgess, PharmD**

### Preceptors



**Tania Vila, PharmD**  
Scientific Director, US Medical  
Affairs, GSK



**Charlene Prazma, PhD**  
Senior Scientific Director, US  
Medical Affairs, GSK

### Fellows




**Justin Veeder, PharmD**  
Second Year Fellow  
UNC Eshelman School of  
Pharmacy



**Catharine Nguyen, PharmD**  
Second Year Fellow  
Temple University School of  
Pharmacy



**Veronica Nguyen, PharmD**  
First Year Fellow  
St. John's University



**Darrian Proco, PharmD**  
First Year Fellow  
UNC Eshelman School of  
Pharmacy



## Global Regulatory Affairs fellowship

**The Global Regulatory Affairs (GRA) fellowship provides practical training and experience in regulatory affairs to help fellows gain expertise in regulatory requirements and strategy pertinent to drug development**

Fellows will develop an in-depth understanding of regulatory affairs and the drug development process from pre-clinical to post-marketing stages. Fellows will establish a strong foundation of experience and knowledge to lead a successful career within the pharmaceutical industry, Food and Drug Administration (FDA), or Contract Research Organizations (CROs).



### Fellowship objectives

- Apply principles of pharmaceutical product development and develop regulatory strategy by using and interpreting regulations and guidelines
- Provide support to the life-cycle management activities pre- and post-approval, for drug and biologic products and gain an understanding of the principles of agency review processes
- Gain an understanding of early and late phase clinical development and gain expertise in the requirements of regulatory submissions
- Understand the various facets that exist within GRA including labeling, advertising and promotion, regulatory intelligence and strategy, chemistry manufacturing and controls (CMC), and non-clinical regulatory
- Obtain valuable foundational knowledge by partaking in the Regulatory Affairs Certification (RAC) course and examination

## Program overview

Global Regulatory Affairs (GRA) fellows may be based out of Upper Providence or Waltham, based on business need, throughout the 2-year duration of the fellowship program.

GSK will recruit at least 2 qualified post-doctoral Regulatory Affairs fellow candidates to support either:

- **Therapeutic Groups (Regulatory Strategy), including Oncology**
- **Chemistry, Manufacturing & Controls (CMC)**

Candidates should identify which position is of interest.

**During the fellowship, the fellow will work with regulatory leaders to gain hands-on experience and have the opportunity to**

- Develop valuable regulatory strategic skills across all phases of drug development and function as an effective project team member
- Prepare regulatory interaction documents and submission packages and interact with regulatory agencies to guide product development
- Develop and maintain awareness of the regulatory landscape to inform drug development
- Participate in departmental initiatives for process improvements and/or regulatory knowledge management

## Sponsor



**Mark DeSiato**  
Vice President,  
Therapeutic Group  
Regulatory Head, GSK



“Fellows are given the opportunity to utilize the knowledge and leadership skills they have obtained from our partnership with UNC and gain hands on experience in the pharmaceutical industry at GSK. The program also assists in identifying and developing emerging talent to potentially support the future GSK business. On behalf of GRA, we very much look forward to working with the fellows over the coming years!”

Mark DeSiato

## Program Director



**Kevin Fitzgerald, BSPHarm**  
Senior Director, Delivery Team Lead  
& Regulatory Expert, Regulatory  
Transformation RPS, GSK

## Program Preceptor



**Shiv Patel, PharmD, RAC**  
Associate Director, Oncology  
Therapeutic Group, Global  
Regulatory Affairs, GSK

## Fellows



**Riddhi Virparia, PharmD, RAC**  
Second Year Fellow  
Oncology Therapeutic Group  
Rutgers University



**Eric Mui, PharmD, RAC**  
Second Year Fellow  
Chemistry, Manufacturing &  
Controls (CMC)  
University of Wisconsin, Madison



**Deanna Rubin, PharmD**  
First Year Fellow  
Oncology Therapeutic Group  
UNC Eshelman School of  
Pharmacy



**Lauren Xu, PharmD, MS**  
First Year Fellow  
Chemistry, Manufacturing &  
Controls (CMC)  
University of Pittsburgh



## Pharmacokinetics/ Pharmacodynamics fellowship

**The Pharmacokinetics/ Pharmacodynamics (PK/PD) fellowship provides practical training and experience needed to successfully obtain a position as a Clinical Pharmacologist in the pharmaceutical industry, academia, or in a clinical setting**

The fellowship emphasizes coursework and hands-on experience focused on the application of population and physiologically-based PK/PD modeling and simulation techniques to guide drug development. Fellows will work on cross-functional teams and contribute to drug development from a clinical pharmacology perspective.



### Fellowship objectives

- Understand the nature and relevance of clinical data evaluations relative to drug development
- Design and implement studies to examine drug absorption, drug disposition, pharmacodynamic endpoints and drug interactions in healthy human volunteers or diseased patient populations
- Understand foundational concepts related to population PK/PD and physiologically-based PK modeling and simulation techniques
- Understand important considerations in clinical trial design and the conduct of clinical investigations in specific patient populations (e.g., pediatrics)
- Perform PK/PD and statistical data analysis using relevant software packages
- Prepare a manuscript, seminar and other scholarly vehicles for communication of scientific results



## Program structure

### Year one

At UNC Eshelman School of Pharmacy, fellows will have the opportunity to

- Engage in didactic and scholarly training via coursework in population and physiologically-based PK/PD modeling and simulation techniques
- Coordinate and support clinical pharmacology, drug pharmacokinetic and metabolism studies and mathematical modeling with UNC Division of Pharmacotherapy and Experimental Therapeutics (DPET) faculty
- Design, conduct and carry out data analysis of clinical pharmacology studies in the academic setting as part of the learning experience

### Year two

Fellows relocate to Upper Providence. At GSK within Clinical Pharmacology Modelling and Simulation (CPMS), fellows will have the opportunity to

- Interact with multi-disciplinary teams to apply state-of-the-art quantitative methodologies to aid the development of compounds in the GSK portfolio; such as population PK/PD analyses, exposure-response, disease progression modeling and clinical trial simulations
- Provide expertise to the design and analysis of first-time-in-human, proof-of-concept, drug-drug interaction or other clinical pharmacology studies
- Contribute to modeling and simulation efforts for quantitative decision making to enhance study design, support candidate selection, provide dose rationale, and/or benchmark against competitor compounds

### Sponsor



**Rajendra Singh, PhD**  
Director, Clinical Pharmacology Modeling and Simulation, GSK

### Program Director



**Daniel Gonzalez, PharmD, PhD**  
Assistant Professor, Division of Pharmacotherapy and Experimental Therapeutics, UNC




“An academic setting like UNC DPET within Eshelman School of Pharmacy, is a phenomenal learning environment for the fellow to become acquainted with the complex techniques that will aid him/her succeed at GSK. While at GSK the fellow will be able to seamlessly transition into the work utilizing GSK’s state of the art capabilities in modeling and simulation projects”

**Daniel Gonzalez, PharmD, PhD**


### Fellows



**Fernando Carreño, PhD**  
Second Year Fellow  
Federal University of Rio Grande do Sul



**Eleni Karatza, PhD**  
First Year Fellow  
National and Kapodistrian University of Athens



# UNC GSK Fellowship Alumni

## Employed at GSK

### Keith Pappa

Head of Clinical Sciences,  
Chief Scientific and  
Medical Office, ViiV

Clinical Research & Drug  
Development fellow  
1985-1986

### Karol LaCroix

Team Leader, SERM,  
Central Safety  
Department, GSK

Clinical Research & Drug  
Development fellow  
1986-1987

### Linda Clayton

Director, SERM, Central  
Safety Department, GSK

Clinical Research & Drug  
Development fellow  
1989-1990

### Lynn Henson

Senior Director,  
SERM, Central Safety  
Department, GSK

Clinical Research & Drug  
Development fellow  
1990-1992

### Amy Meadowcroft

Director, Clinical  
Development, Medicine  
Delivery, GSK

Clinical Research & Drug  
Development fellow  
1996-1998

### Sarah Roberts

Manager, Global  
Regulatory Affairs,  
Labeling, GSK

Clinical Research & Drug  
Development fellow  
1998-2000

### Susan Ford

Director, Clinical  
Pharmacology, GSK

Pharmacokinetics &  
Pharmacodynamics fellow  
2000-2002

### Michael Lim

Director, EPCS, Global  
Oncology Franchise, GSK

Drug Development fellow  
2001-2003

### Purav Bhatt

Manager, Clinical  
Development, Medicine  
Delivery, GSK

Clinical Research & Drug  
Development fellow  
2012-2014

### Christine Trezza

Director, Medical  
Governance & Operations,  
Global Medical Affairs, ViiV

Clinical Research & Drug  
Development fellow  
2013-2015

### Michael Bogart

Manager, US Value  
Evidence Outcomes, GSK

Pharmaceutical Outcomes  
Research fellow  
2013-2015

### Jennifer Kim Cremer

Manager, Clinical  
Development, Respiratory  
& Specialty, GSK

Clinical Research & Drug  
Development fellow  
2014-2016

### Kristina Vishnevetskaya

Manager, Oncology  
Therapeutic Group, Global  
Regulatory Affairs, GSK

Global Regulatory Affairs  
fellow  
2017-2019

### Hitesh Patel

Medical Information  
Scientist, Medical Affairs,  
GSK

Medical Affairs fellow  
2017-2019

### Kwadwo Yeboah

Manager, Oncology  
Therapeutic Group, Global  
Regulatory Affairs, GSK

Global Regulatory Affairs  
Fellow  
2018-2020

### Lauren Hothem

MSL, Medical Affairs, GSK

Medical Affairs Fellow  
2018-2020



## EMPLOYED AT UNC

### Denise Rhoney

Associate Dean for Curricular  
Innovation, PACE, UNC Eshelman  
School of Pharmacy

Clinical Research & Drug Development  
fellow  
1993-1995

### Craig R. Lee

Associate Professor of Pharmacy,  
DPET, UNC Eshelman School of  
Pharmacy

Clinical Research & Drug Development  
fellow  
2000-2002



### **Katy Moore**

**Global Head, Clinical Pharmacology, ViiV Research & Development**

Pharmacokinetics & Pharmacodynamics Clinical Pharmacology fellow  
1993-1995

### **Patrick Wire**

**Senior Director, Therapeutic Group, Global Regulatory Affairs, GSK**

Clinical Research & Drug Development; Pharmacokinetics fellow  
1993-1995

### **Melissa Ellis**

**Director, SERM, Central Safety Department, GSK**

Clinical Research & Drug Development fellow  
1994-1996

### **Rob Kustra**

**Director, SERM, Central Safety Department, GSK**

Clinical Research & Drug Development fellow  
1995-1997

### **Lakshmi Vasist**

**Director, Clinical Pharmacology, GSK**

Pharmacokinetics & Pharmacodynamics fellow  
2004-2006

### **Justin Koteff**

**Director, Scientific Communications, Strategy & Medical Information, ViiV**

Clinical Research & Drug Development fellow  
2009-2011

### **Bryant Tran**

**Scientific Director, US Medical Affairs, GSK**

Clinical Research & Drug Development fellow  
2009-2011

### **Elizabeth Blair**

**Director, Clinical Development, Scientific Medical Office, ViiV**

Clinical Research & Drug Development fellow  
2012-2014

### **Elizaveta Budko**

**Manager, Therapeutic Group, Global Regulatory Affairs, GSK**

Global Regulatory Affairs fellow  
2014-2016

### **Brittany Dustman**

**Associate Director, Oncology Therapeutic Group, Global Regulatory Affairs, GSK**

Global Regulatory Affairs fellow  
2016-2018

### **Shiv Patel**

**Associate Director, Oncology Therapeutic Group, Global Regulatory Affairs, GSK**

Global Regulatory Affairs fellow  
2016-2018

### **Prani Paka**


**Scientific Director, Global Medical Affairs Oncology, GSK**

Medical Affairs fellow  
2016-2018

### **Alexis Williams**

**Global Medical Information Leader, Medical Affairs, GSK**

Medical Affairs Fellow  
2018-2020



## Application and Eligibility

The UNC Eshelman School of Pharmacy and GSK Pharmaceutical Industry Fellowships commence in July 2021.

Applicants must submit an online application including a letter of interest, CV, unofficial transcripts, and 3 letters of recommendation.

Interviews will be arranged virtually for selected candidates.



### US Medical Affairs, Global Regulatory Affairs and PK/PD



Visit <http://pharmacydpetfellowships.web.unc.edu> for application instructions and deadlines.

Early applications are highly encouraged





In partnership with



**ESHELMAN SCHOOL  
OF PHARMACY**



## **GSK**

**Research Triangle Park**  
5 Moore Dr  
Research Triangle Park  
NC  
27709

### **Upper Providence**

1250 S Collegeville Rd,  
Collegeville  
PA  
19426

### **Waltham**

1000 Winter St  
Waltham  
MA  
02451

[www.gsk.com](http://www.gsk.com)

## **UNC Eshelman School of Pharmacy**

**The University of North Carolina  
at Chapel Hill**  
301 Pharmacy Lane  
Chapel Hill  
NC  
27599

[www.pharmacy.unc.edu](http://www.pharmacy.unc.edu)